New data presented at AIDS 2020 show the long-acting injectable drug cabotegravir proved superior to daily oral TDF/FTC for MSM and transgender women.
People living with HIV in the U.S. are experiencing increases in body mass index at a rate three times greater than that of the general U.S. population, according to new research presented at AIDS 2020.
Multiple U.S. health agencies have released HIV-specific information, and research on HIV and the novel coronavirus is trickling in. Here's what health care providers need to know.
July 1, 2020: Quantifying bone fracture risks; real-world lipid effects of switching to TAF; pulmonary function impairment in MSM; immunomodulatory drugs and viral load blips.
A newly published study linking HIV medication to reduction in COVID-19 risk has many problems, experts warn.
June 25, 2020: 25 years of HOPS; successes of San Francisco’s test-and-treat program; missed opportunities to test people who inject drugs; how patient-provider trust can curb prescribing cascades.
June 18, 2020: Existing evidence-based interventions aren't enough to close HIV's racial gap; transgender patient outcomes in the HIV care continuum; meeting long-term needs of formerly incarcerated people; acute respiratory illness severity and HIV status.
Kaiser Permanente’s 2-1-1 pre-exposure prophylaxis (PrEP) program shows event-driven dosing works.
June 11, 2020: Diagnosis rates within a year of infection; rates of intentional non-daily PrEP use; neurological development in children of birth parents with HIV; point-of-care urine test to assess tenofovir levels.
When People Stop Newer HIV Meds, Time to Viral Rebound Not Better Than With Older Antiretroviral Therapy, NIH Study Finds
Researchers are trying to understand treatment interruptions as part of work to develop a future HIV cure and therapies that will not involve medications.